AI Article Synopsis
- The gut microbiome and the intestinal immune system play key roles in inflammatory bowel diseases (IBD), with short-chain fatty acids (SCFAs) being a significant signaling factor produced by gut bacteria.
- SCFAs like acetate, propionate, and butyrate influence host metabolism and immune responses, impacting energy metabolism, intestinal barrier function, and overall disease activity in IBD.
- More research is needed to explore gut microbiome cross-feeding mechanisms and the therapeutic potential of SCFAs, while randomized controlled trials should assess the clinical effects of SCFA administration.
Article Abstract
The gut microbiome and the intestinal immune system are driving contributors to inflammatory bowel diseases (IBD). Both have an important signalling factor in common: short-chain fatty acids (SCFAs). SCFAs (acetate, propionate and butyrate) are produced by bacterial fermentation in the gut and exert several effects on host metabolism and immune system. This review provides an overview of the current knowledge of these effects, with specific focus on energy metabolism, intestinal barrier, immune system, and disease activity in IBD. To conclude, more research is needed on the cross-feeding mechanisms in the gut microbiome, as well as on the therapeutic potential of SCFAs on different disease models. Also randomized controlled trials and prospective cohort studies should investigate the clinical impact of SCFA administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047503 | PMC |
| http://dx.doi.org/10.1016/j.ebiom.2021.103293 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!